Melanotan I Photoprotection Research and MC1R

Melanotan I is a synthetic 13-amino-acid peptide built on the full alpha-MSH backbone, modified with two substitutions, norleucine at position 4 and D-phenylalanine at position 7, that give it the formal name [Nle4, D-Phe7]-alpha-MSH. It is also referred to as NDP-MSH in the scientific literature. These substitutions confer substantially greater potency and a much longer duration of action than the native hormone, along with resistance to enzymatic degradation. Unlike Melanotan II, which is a cyclic, non-selective heptapeptide, Melanotan I retains a linear structure closer to native alpha-MSH and shows relative selectivity for the melanocortin 1 receptor (MC1R) over the other melanocortin receptor subtypes.

This is an important structural distinction from Melanotan II, discussed elsewhere on this site, which is non-selective across MC1R, MC3R, MC4R, and MC5R and carries a different research and safety profile as a result. Melanotan I’s relative MC1R selectivity is the structural basis for its more focused pigmentation research and, ultimately, its regulatory history described below.

Early mechanistic work by Hadley and colleagues (1985) examined Melanotan I in a Cloudman S91 melanoma cell line and found it to be roughly 100-fold more effective than native alpha-MSH at stimulating tyrosinase, the rate-limiting enzyme in melanin synthesis. The research also reported an unusually sustained effect: cells exposed briefly to Melanotan I continued to show elevated tyrosinase activity for up to six days after the peptide was removed from the culture medium, a duration far exceeding that seen with native alpha-MSH. The authors described this as an essentially irreversible activation of the melanogenic pathway, distinguishing the analog’s pharmacology from that of the endogenous hormone.

This sustained MC1R engagement, driving cyclic AMP production and downstream tyrosinase activity, is the mechanistic basis for pigmentation that develops independent of ultraviolet exposure, a property that shaped nearly all subsequent research on the compound.

Dorr and colleagues (1988) conducted early toxicology studies of Melanotan I in mice, administering the compound both topically and by injection over 4 to 12 weeks. The research found no toxic effects on organs, hematologic indices, or weight gain, with only a slight increase in triglyceride and platelet levels noted after prolonged weekly dosing. The authors explicitly framed the compound as entering Phase I clinical trials for potential use in hypomelanotic disorders such as vitiligo and for pharmacologic tanning without sunlight exposure, language that captures the original research direction for this peptide.

Human pigmentation research followed. Levine and colleagues (1991), publishing in JAMA, administered this same NDP-alpha-MSH compound to human volunteers by subcutaneous injection and reported measurable skin darkening without any ultraviolet exposure, providing early clinical evidence that the mechanism observed in cell culture translated to pigmentation in humans.

The same peptide sequence studied as Melanotan I underwent formal clinical development under the name afamelanotide, marketed as Scenesse, for a rare and severe disease called erythropoietic protoporphyria (EPP), a photodermatosis in which sunlight exposure causes excruciating pain. Langendonk and colleagues (2015), publishing in the New England Journal of Medicine, reported two multicenter, randomized, double-blind, placebo-controlled trials of a subcutaneous implant containing 16 mg of afamelanotide. In the United States study, the median duration of pain-free sun exposure after 6 months was 69.4 hours in the afamelanotide group versus 40.8 hours with placebo. In the European Union study, phototoxic reactions were reduced from 146 to 77 events, and quality of life improved in both trials.

This research supported the compound’s approval by European regulators and, in October 2019, by the U.S. Food and Drug Administration, specifically for EPP. A follow-up immunogenicity study by Lengweiler and colleagues (2015) found no antibody response against the peptide in 23 of 26 EPP patients treated for up to 6 years, supporting a favorable long-term tolerability profile in that population.

This regulatory history creates a distinction worth stating with precision, since it is a point of genuine confusion in this space. Afamelanotide (Scenesse) is a specific, approved pharmaceutical product manufactured by Clinuvel Pharmaceuticals, formulated as a biodegradable, controlled-release subcutaneous implant containing 16 mg of the peptide, and its EU and FDA approvals apply specifically to that implant formulation for the treatment of EPP. Kim and Garnock-Jones (2016), reviewing the compound in the American Journal of Clinical Dermatology, described afamelanotide as a first-in-class melanocortin-1 receptor agonist approved in the EU for this specific indication and route of administration.

The Melanotan I supplied by Badger Compounds is the same peptide sequence, [Nle4, D-Phe7]-alpha-MSH, provided as a lyophilized powder for laboratory research use. It is not manufactured, formulated, or administered as the approved implant, and it carries none of the regulatory approvals that apply to Scenesse. Sharing a peptide sequence with an approved drug does not mean a research-grade compound is equivalent to, or interchangeable with, that approved product. This distinction is central to accurate, compliant research use of Melanotan I.

Preclinical and clinical literature has examined Melanotan I across several interconnected research contexts: